A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression.

Huajun ZhaoXianyu ShaoYating YuLulu HuangNarh Philip AmorKun GuoChangzhen WengWeijun ZhaoAilu YangJiesen HuHongbao YangZhenguang LiuQiuju HanLeilei ShiShiyu SunJian Zhang Ang Lin Yong Yang

Published in: NPJ vaccines (2024)

Here we report on the development and comprehensive evaluations of an mRNA vaccine for chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by viral vector-mediated HBV transfection (pAAV-HBV1.2 and rAAV8-HBV1.3), this vaccine demonstrates sufficient and persistent virological suppression, and robust immunogenicity in terms of induction of strong innate immune activation, high-level virus-specific antibodies, memory B cells and T cells. mRNA platform therefore holds prospects for therapeutic vaccine development to combat CHB.

Keyphrases

hepatitis b virus
liver failure
innate immune
mouse model
binding protein
sars cov
antiretroviral therapy
hiv infected patients
working memory
current status
liver fibrosis